Accession Number:

ADB275851

Title:

Role of Sulfation Pharmacogenetics in Breast Cancer Treatment with 2-Methoxyestradiol

Descriptive Note:

Final rept. 1 Oct 2000-30 Sep 2001

Corporate Author:

MAYO FOUNDATION ROCHESTER MN

Personal Author(s):

Report Date:

2001-10-01

Pagination or Media Count:

15.0

Abstract:

2-ME2 is an endogenous estrogen metabolite that inhibits the proliferation of breast and other human cancer cell lines. 2-ME2 also has potent anti-angiogenic and anti-tubulin properties, and it may inhibit estrogen- induced carcinogenesis in the mammary gland. We set out to test the hypothesis that 2-ME2 might be a substrate for sulfate conjugation and, therefore, that individual variations in the sulfation of 2-ME2 might contribute to individual differences in its metabolism, pharmacokinetics and therapeutic efficacy. As a first step, we tested 2-ME2 as a substrate for 7 human sulfotransferase SULT isoforms -- as well as all of the common allozymes for SULT 1 Al and 1A2.

Subject Categories:

  • Biochemistry
  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

APPROVED FOR PUBLIC RELEASE